secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001213900-25-041049
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics Q1 net loss widens to $3.8M; cash at $7.3M; tecarfarin development advances
--------------------------------------------------------------------------------

- Net loss of $3.8M for Q1 2025 vs $1.7M in Q1 2024; R&D expense $1.7M (up from $0.6M), G&A $2.3M (up from $1.1M).
- Cash and equivalents $7.3M at Mar 31, 2025, down from $10.0M at Dec 31, 2024; 1.9M common shares outstanding.
- Appointed Dr. James Ferguson as CMO in February 2025 to lead clinical development and business development.
- FDA Type D meeting in Feb 2025 provided guidance for Phase 3 tecarfarin trial; Abbott collaboration announced for TECH-LVAD trial.
- Completed API manufacturing transfer from Asia to U.S. CDMO; LVAD market research projects near doubling by 2032.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025041049/0001213900-25-041049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025041049/ea0241397-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-041049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer